CST, 19859SF, TET2 (D6C7K) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying TET2 mouse. Validated for Western Blotting,Immunofluorescence (Immunocytochemistry),Flow Cytometry (Fixed/Permeabilized). Highly specific and rigorously validated in-house, TET2 (D6C7K) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #19859) is ready to ship. Product Usage Information This product is the carrier free version of product #36449. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 36449 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity TET2 (D6C7K) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total TET2 protein. Species Reactivity: Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1640 of Mouse TET2 protein. Background Methylation of DNA at cytosine residues is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting, and mammalian development (1,2). 5-methylcytosine is a repressive epigenetic mark established de novo by two enzymes, DNMT3a and DNMT3b, and is maintained by DNMT1 (3, 4). 5-methylcytosine was originally thought to be passively depleted during DNA replication. However, subsequent studies have shown that Ten-Eleven Translocation (TET) proteins TET1, TET2, and TET3 can catalyze the oxidation of methylated cytosine to 5-hydroxymethylcytosine (5-hmC) (5). Additionally, TET proteins can further oxidize 5-hmC to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), both of which are excised by thymine-DNA glycosylase (TDG), effectively linking cytosine oxidation to the base excision repair pathway and supporting active cytosine demethylation (6,7). TET2 is the most frequently mutated gene in myeloid dysplastic syndrome (MDS), a dysplasia of myeloid, megakaryocytic, and/or erythroid cell lineages, of which 30% progress to acute myeloid leukemia (AML) (8, 9). It is also mutated in diffuse large B-cell lymphoma (10). TET2 protein expression is often reduced in solid tumors such as prostate cancer, melanoma, and oral squamous cell carcinoma (11-13). Alternate Names Ayu17-44; Ayu17-449; E130014J05Rik; Kiaa1546; Methylcytosine dioxygenase TET2; MGC37385; mKIAA1546; Probable methylcytosine dioxygenase TET2; Protein Ayu17-449; tet methylcytosine dioxygenase 2; tet oncogene 2; tet oncogene family member 2; Tet2 Specification REACTIVITY: M SENSITIVITY: Endogenous MW (kDa): 280 Source/Isotype: Rabbit IgG